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ABSTRACT Crimean-Congo hemorrhagic fever virus (CCHFV) is a bunyavirus caus-
ing severe hemorrhagic fever disease in humans, with high mortality rates. The re-
quirement of a high-containment laboratory and the lack of an animal model ham-
pered the study of the immune response and protection of vaccine candidates.
Using the recently developed interferon alpha receptor knockout (IFNAR/) mouse
model, which replicates human disease, we investigated the immunogenicity and
protection of two novel CCHFV vaccine candidates: a DNA vaccine encoding a
ubiquitin-linked version of CCHFV Gc, Gn, and N and one using transcriptionally
competent virus-like particles (tc-VLPs). In contrast to most studies that focus on
neutralizing antibodies, we measured both humoral and cellular immune responses.
We demonstrated a clear and 100% efﬁcient preventive immunity against lethal CCHFV
challenge with the DNA vaccine. Interestingly, there was no correlation with the
neutralizing antibody titers alone, which were higher in the tc-VLP-vaccinated mice.
However, the animals with a lower neutralizing titer, but a dominant cell-mediated
Th1 response and a balanced Th2 response, resisted the CCHFV challenge. Moreover,
we found that in challenged mice with a Th1 response (immunized by DNA/DNA
and boosted by tc-VLPs), the immune response changed to Th2 at day 9 postchal-
lenge. In addition, we were able to identify new linear B-cell epitope regions that
are highly conserved between CCHFV strains. Altogether, our results suggest that a
predominantly Th1-type immune response provides the most efﬁcient protective im-
munity against CCHFV challenge. However, we cannot exclude the importance of
the neutralizing antibodies as the surviving immunized mice exhibited substantial
amounts of them.
IMPORTANCE Crimean-Congo hemorrhagic fever virus (CCHFV) is responsible for
hemorrhagic diseases in humans, with a high mortality rate. There is no FDA-
approved vaccine, and there are still gaps in our knowledge of the immune re-
sponses to infection. The recently developed mouse models mimic human CCHF dis-
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ease and are useful to study the immunogenicity and the protection by vaccine
candidates. Our study shows that mice vaccinated with a speciﬁc DNA vaccine were
fully protected. Importantly, we show that neutralizing antibodies are not sufﬁcient
for protection against CCHFV challenge but that an extra Th1-speciﬁc cellular re-
sponse is required. Moreover, we describe the identiﬁcation of ﬁve conserved B-cell
epitopes, of which only one was previously known, that could be of great impor-
tance for the development of diagnostics tools and the improvement of vaccine
candidates.
KEYWORDS Crimean-Congo hemorrhagic fever virus, DNA vaccines, Th1/Th2
responses, VLP, neutralizing antibodies
Crimean-Congo hemorrhagic fever virus (CCHFV) is a member of the Nairovirusgenus of the family Bunyaviridae. Viruses within this family possess three single-
stranded RNA segments of negative sense. The large (L) segment encodes the RNA-
dependent RNA polymerase, the medium (M) segment encodes the two structural
glycoproteins (Gn and Gc) and a nonstructural protein (Nsm), and the small (S) segment
encodes the nucleocapsid protein (N) and the nonstructural protein NSs (1). CCHFV is
present in Asia, Africa, the Middle East, and Europe; in humans, it causes severe
hemorrhagic disease with a reported mortality rate of up to 30%. CCHFV is transmitted
through tick bites and/or through contact with viremic blood or tissues from patients
or infected livestock (2).
The wide geographical distribution, mode of transmission, severity of the disease,
and high mortality rate in humans, together with therapeutic difﬁculties and lack of an
FDA-approved vaccine, make CCHFV a signiﬁcant threat to public health.
Progress with CCHFV research has been severely hampered by the lack of a suitable
animal model and by the requirement of high-containment laboratories to handle the
virus. Newborn mice succumb to infection (3), but due to their immature immune
systems, they cannot be used to assess vaccine efﬁcacy. Recently, adult small-animal
models have been developed using mice deﬁcient in the antiviral type I interferon (IFN)
signaling pathway, either in the type I IFN receptor (IFNAR) or in STAT1 (4, 5). CCHFV
infection in IFNAR-knockout mice reproduces human disease via a variety of inoculation
routes, including intradermal (i.d.)/subcutaneous injection, which is intended to mimic
human infection by tick bite (6).
The only available vaccine is an inactivated virus produced on suckling mouse brain
(inactivated by chloroform, heated at 58°C, and adsorbed on aluminum hydroxide). This
vaccine is currently used in Bulgaria and originated from the Union of Soviet Socialist
Republics in 1970 (7). Since 1974 it has been used to immunize mainly military and
medical personnel, farmers, and persons living or working in regions of endemicity. A
4-fold reduction in the number of reported Crimean-Congo hemorrhagic fever cases in
Bulgaria has been observed over a 21-year period following initiation of vaccination (8,
9). A recent study found that this vaccine elicited both a cellular and humoral response
to CCHFV (9), but neutralizing antibody titers were low, even in individuals that who
had received four doses (3, 7). Controlled studies on protective efﬁcacy have not been
reported with this vaccine, and, due to its crude preparation, it is unlikely to gain
widespread international regulatory approval. There is, therefore, at present no safe
and effective, commercially available vaccine against CCHFV.
Previously, Spik and colleagues (10) had demonstrated that a DNA-based vaccine
expressing the CCHFV M segment induced neutralizing antibodies in approximately
half of vaccinated mice; however, the lack of a challenge model at the time did not
allow testing of protection. Another vaccine candidate using transgenic tobacco leaves
expressing Gn and Gc was fed to mice and induced speciﬁc IgG and IgA. However,
antibodies were not tested for virus neutralization (NT) capacity, and this oral vaccine
could not be tested for protection either (11). Neither of these studies investigated
cellular immune responses.
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Recently, Buttigieg and colleagues (3) demonstrated that the attenuated poxvirus
vector modiﬁed vaccinia virus Ankara expressing the CCHF virus glycoproteins (MVA-
GP) raised cellular and humoral immune responses in two mouse strains, including
IFNAR knockout mice, which are susceptible to CCHF disease. This vaccine protected all
recipient animals from lethal disease in a challenge model adapted to represent
infection via tick bite. Histopathology and viral load analysis of protected animals
conﬁrmed that they had been exposed to the challenge virus even though they did not
exhibit clinical signs. This is the ﬁrst experimental demonstration of efﬁcacy by a CCHF
vaccine.
Virus-like particles (VLPs) result from the self-assembly of recombinant viral proteins.
Since they adopt a protein conformation and antigenicity similar to the native virus,
VLPs are gaining more and more interest in the vaccine ﬁeld, especially for emerging
infectious disease viruses (12). Indeed, they can elicit strong humoral and cellular
responses, and their lack of a viral genome renders them safer to use as vaccine than
recombinant or attenuated/inactivated virus. We recently developed a transcriptionally
competent VLP (tc-VLP) system for CCHFV (13) in which the particles display the two
glycoproteins Gc and Gn at their surfaces and contain a reporter minigenome encap-
sidated by the nucleoprotein and bound by the viral polymerase. These tc-VLPs can be
neutralized by speciﬁc CCHFV antiserum. For Rift Valley fever virus (RVFV), a bunyavirus
of the Phlebovirus genus, tc-VLPs have been shown to induce innate immune responses
and neutralizing antibody titers and to protect mice from lethal challenge without the
need of an adjuvant (14, 15).
Here, we investigated the immunogenicity and protective efﬁcacy of two novel
vaccine candidates, a DNA vaccine coding for CCHFV Gc, Gn, or N and another using
transcriptionally competent virus-like particles (tc-VLPs) (13), in the IFNAR/ mouse
model and characterized the protecting humoral and cellular immune responses.
RESULTS
Antibody responses in immunized IFNAR/ mice. The IFNAR/ mice were
immunized with DNA plasmids encoding a ubiquitin (Ub)-linked version of CCHFV Gc,
Gn, and N and/or with transcriptionally active virus-like particles (tc-VLPs). Ubiquitin-
linked antigens may promote cellular responses more efﬁciently than unmodiﬁed
antigens, thus broadening the immune response elicited. This has been shown for Rift
Valley fever virus, another bunyavirus, to enhance levels of speciﬁc antibodies and to
induce a high degree of protection from challenge (16). The immunization schedules
for IFNAR/ mice with the CCHFV antigens are depicted in Fig. 1A. The serum IgG
responses to the CCHFV antigens were analyzed by enzyme-linked immunosorbent
assay (ELISA). As shown in Fig. 1B, mice that were immunized with tc-VLPs alone
reached the highest serum titers after two immunizations. However, after the second
booster, antibody levels to CCHFV antigen increased dramatically for groups A and B in
contrast to levels of the group which received only tc-VLPs (Fig. 1B).
To study neutralization (NT) speciﬁcity of antibodies raised by the DNA plasmids
and/or tc-VLPs, we divided the mice in each group in two subgroups: those with the
highest anti-CCHFV serum IgG antibody responses (subgroups A1, B1, and C1, with sera
from three or four mice each) and those with the lowest anti-CCHFV serum IgG
antibody responses (subgroups A2, B2, and C2, with sera from three mice each). The
sera were pooled in each subgroup and were used for future studies. All immunized
mouse groups responded by developing neutralizing antibodies (Fig. 1C). However, the
mice that had been immunized exclusively with tc-VLPs (group C) consistently dis-
played higher neutralizing antibody titers than mice that received only DNA. Group B
that received DNA twice and tc-VLPs once showed higher neutralizing antibody titers
than mice that received only DNA.
Survival by Kaplan-Meier analysis.Mouse survival was monitored for 10 days after
lethal challenge with CCHFV. All mice in group A and all mice except one in group B
survived the whole observation period after challenge. The full comparison of survival
between immunized mouse groups and non-CCHFV-immunized mice is shown in
Vaccine against CCHFV Journal of Virology
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Fig. 2A. The body weight of all mice at sacriﬁce (or at day of death due to CCHFV
infection) is summarized in Fig. 2B. All A129 IFNAR/ mice receiving only CCHFV DNA
plasmids (group A) survived without signiﬁcant body weight loss (Fig. 2B). Group D
(immunized by empty plasmids) animals all succumbed within 3 days, and the two
actively immunized groups of mice survived at rates of 100% in the DNA plasmid-only
group (group A) and of 80% in the DNA and tc-VLP group (group B). Surprisingly, in
mice given only tc-VLPs, we found only a 40% survival rate and a signiﬁcant body
weight loss. Viral RNA load was analyzed by reverse transcription-PCR (RT-PCR) in blood,
FIG 1 (A) A schematic drawing illustrating the immunization schedule for the A129 IFNAR/ mice used.
Four groups of mice were compared: group A (three doses of CCHF-DNA-plasmids i.d. by Biojector
administration), group B (two doses of CCHF-DNA-plasmids i.d. by Biojector administration and a ﬁnal
booster with CCHF-VLPs i.p.), group C (three doses of VLPs alone by i.p. injection), and group D
(empty-DNA plasmids i.d. by Biojector administration). Immunizations were performed with 3-week
intervals. Lethal CCHFV challenge was delivered by i.p. injection at 6 weeks post-ﬁnal immunization. (B)
Box plot representation of the total anti-CCHFV serum IgG titers after the second and third immuniza-
tions of the three groups of A129 IFNAR/ mice. The box encloses 50% of the data, with the median
value indicated by a horizontal line; the limits of the box represent the upper and lower quartiles.
Whiskers mark the maximum and minimum values, excluding outliers. Filled circles represent outliers,
deﬁned as values greater than the upper quartile or smaller than the lower quartile, 1.5 the
interquartile distance. (C) Geometric mean of anti-CCHFV neutralizing serum titers/vaccine-receiving
group. In each group the sera were pooled into two pools/subgroup based on the CCHFV ELISA IgG
titers. In each subgroup the three mice with the highest serum IgG ELISA titers were pooled with equal
volumes (serum pool A1, B1, and C1, respectively), and the mice with lowest serum IgG ELISA titers per
group were pooled into pools indicated as A2, B2, and C2, respectively. OD, optical density.
Hinkula et al. Journal of Virology
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spleen, and liver (Fig. 2C to E) at the day of sacriﬁce. In control group D (nonimmunized)
and in mice immunized with tc-VLPs (group C), we found high levels of viral RNA in all
tested tissues. In contrast, in groups A and B, we could clearly demonstrate that mice
cleared the virus from their blood as there was no viral RNA detectable in their sera (Fig.
2C). However, there was detectable viral RNA in the spleen and liver of the survivors
FIG 2 (A) Kaplan-Meier graph showing the survival pattern for each group of vaccinated and CCHFV-challenged
A129 IFNAR/ mice. (B) The mean percentage of body weight change/group is shown post-CCHFV challenge
(mean and 95% standard deviation shown for each group). Group A1 data represent animals with highest
neutralizing serum antibody titers, and group A2 data represent two mice with the lowest serum neutralizing titers.
Group B1 data show body weight changes in animals with highest neutralizing serum antibody titers, and group
B2 data represent the two mice with the lowest serum neutralizing titers. Group C data represent mice immunized
with three doses of tc-VLPs before CCHFV challenge. Group C1 data show body weight changes in animals with
highest neutralizing serum antibody titers, and group C2 data represent two mice with the lowest serum
neutralizing titers. (C to E) Quantitative mean CCHF viral RNA levels in serum (C), spleen (D), and liver (E) per group,
as indicated.
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(groups A and B). The level of viral RNA in spleen and liver in groups A and B was 103
to 104 times less than that in control group D and in group C. To investigate whether
infectious virus was present at the end of the study in these organs, homogenized
supernatants of spleen and liver tissue from survivors (groups A and B) and nonimmu-
nized or tc-VLP-immunized mice were incubated with Vero cells for 72 h. Cells were
ﬁxed at 72 h postinfection (hpi) and analyzed by immunoﬂuorescence assay (IFA) for
the presence of CCHFV N protein. In contrast to our ﬁndings for control group D and
the tc-VLP-immunized group C, we could not detect any infected cells in the cell culture
infected with homogenate organs from groups A and B (data not shown). These results
suggest that the small amounts of RNA detected in spleen and liver from groups A and
B are unlikely to represent infectious virus particles. However, it is possible that the
number of infectious virus particles in these homogenized organs was too low for
detection with IFA.
Cytokine response in IFNAR/ mice before the challenge. The prechallenge
sera from the mice in groups A to D were monitored for their Th1 (Fig. 3A to D) and Th2
(Fig. 3E to H) cytokine proﬁles. The animals in group A and group B showed levels of
the Th1 cytokines IFN-, interleukin-2 (IL-2), IL-12p70, and tumor necrosis factor alpha
(TNF-) that were signiﬁcantly higher than those recorded for group C and the
negative-control animals (Fig. 3A to D). In contrast, in group C levels of IL-4, IL-5, IL-10,
and granulocyte-macrophage colony-stimulating factor (GM-CSF) were signiﬁcantly
higher than those recorded for groups A and B and the negative-control animals (Fig.
3E to H). This suggests the induction of a Th1-type immunity in DNA-immunized mice
and of a Th2-type immunity in tc-VLP-immunized mice.
Cytokine response of IFNAR/mice after the challenge. The cytokine proﬁle for
Th1 and Th2 responses was also investigated postchallenge in the surviving mice of
groups A and B, whereas very small amounts of available sera prevented us from
performing cytokine analyses for groups C and D.
In both groups A and B the levels of IFN-, IL-2, IL-12p70, and TNF- were
signiﬁcantly higher than those in the negative-control sera that were collected prior
to immunizations (P  0.001), again indicating a Th1-type immunity in the DNA-
immunized mice (Fig. 4A to D).
In addition, we found that both group A and group B (Fig. 4E to H) showed
signiﬁcantly higher levels of IL-4 than the control group (P 0.007 to 0.011), while only
group A showed signiﬁcantly higher levels of IL-5 and GM-CSF than the control group
of nonimmunized or challenged mice.
Most interestingly, we found that the Th1 cytokine responses in groups A and B
were shifted toward Th2 cytokine responses at 9 days postchallenge (Fig. 5A to H).
IgG subclass determination. We determined the subclasses of IgG antibodies to
CCHFV as an indicator of Th1 and Th2 responses. For all groups of immunized mice,
measurements were again separately performed for pooled sera with high total IgG
responses (A1, B1, and C1) and pooled sera with low total IgG responses (A2, B2, and
C2). All immunized mice clearly responded with IgG1, IgG2a, and IgG2b but not with
IgG3, albeit the IgG2b responses constituted a small proportion of the total response
in all groups (Fig. 6). The dominating subclasses were IgG1 and IgG2a, but response
proﬁles varied between groups. All mice in group A (mice receiving only DNA plasmids)
showed a higher IgG2a response than IgG1 response before the challenge, again
indicating a Th1-type immune proﬁle. Interestingly, the proﬁle for group A2 was
reversed after the challenge. In group B (two DNA plasmid immunizations and one
tc-VLP immunization), all mice responded with a predominantly IgG2a serum response;
however, levels in these mice indicated slightly higher IgG1 responses than in group A.
It should be noted that the data from cytokine proﬁling (Fig. 5) suggest that groups A1
and -2 and groups B1 and -2 shift from Th1 to Th2 responses.
The third group of mice (C) (three doses of CCHFV tc-VLPs) had a clearly greater IgG1
than IgG2a response; however, group C1 had a predominantly IgG1 response in
Hinkula et al. Journal of Virology
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contrast to the C2 group, which demonstrated a relatively balanced IgG1 and IgG2a
response before challenge. The proportion of IgG1 clearly dominated IgG2a in all mice
in group C after challenge.
Altogether, we ﬁnd that a clear difference in the Th1/Th2-type proﬁles evolved in
the two types of immunization schedules, with DNA plasmid immunizations resulting
in a predominantly Th1-type immunity and the VLP-based immunized animals dem-
onstrating a predominantly Th2-type immune response.
B-cell epitopes. Seven linear B-cell epitopes in the CCHFV envelope proteins could
be identiﬁed by screening of a synthetic peptide library with serum samples collected
after challenge with CCHFV. The most frequent serum IgG responses (9/10 tested serum
samples) were seen with a peptide representing the N-terminal Gn protein: CSIGSVN
FIG 3 (A to D) Th1 cytokine determination in serum samples collected after two (A2, B2, C2) and three (A3, B3, C3) immunizations before challenge, from the
four groups (A, B, C, and D). Each of the four panels illustrates individual mouse serum levels and group geometric mean levels at 95% conﬁdence intervals
of IFN-, IL-2, IL-12p70, and TNF-, respectively. (E to H) Th2 cytokine determination in serum samples collected after two (A2, B2, C2) and three (A3, B3, C3)
immunizations but before challenge, from the four groups (A, B, C, and D). Each of the four panels illustrates individual mouse serum levels and group geometric
mean levels at 95% conﬁdence intervals of IL-4, IL-5, IL-10, and GM-CSF, respectively. A Mann-Whitney test was made for group-wise comparison, and a P value
of 0.05 was considered signiﬁcant. n.s., not signiﬁcant.
Vaccine against CCHFV Journal of Virology
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GFEIESHKCYCSL/IESHKCYCSLFCCPYCRHCS. The second most common serum IgG re-
sponses (6/10) were against the Gc epitope RLTSDGLARHVTQCPKRKEK/VTQCPKRKEKV
EETELYLNL, 5/10 sera reacted with the mucin-like antigen epitopes TINCINLRASVFKEH
REIEI and KIGKASTGFRKLLSEEPGDD, and 6/10 sera reacted to the Gc epitope LKGDRV
NGHLIHKIESHFNT (Table 1). Interestingly, reactivity toward the mucin-like domain (MLD)
epitopes could be predominantly seen in sera from mice of group B (4/5 tested serum
samples), whereas only one individual serum sample from group A (1/5 tested serum
samples) seemed to show an antibody response. Alignment of the identiﬁed B-cell epitopes
in the Gn and Gc regions give an indication that they could be considered to represent
pan-strain epitopes (data not shown). This ﬁnding could be of high interest for the
development of diagnostic tools as well as new vaccine strategies.
FIG 3 (Continued)
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FIG 4 (A to D) Cytokine determination in serum samples collected from two groups, A and B, of immunized mice
postchallenge. An analysis is shown of levels of Th1-pattern cytokines prior to experimental CCHFV challenge. Each of the four
panels illustrates individual mouse serum levels in duplicate and group geometric mean levels at 95% conﬁdence intervals of
IFN-, IL-2, IL-12p70, and TNF-, respectively. (E to H) Cytokine determination in serum samples collected from two groups,
A and B, of immunized mice postchallenge. An analysis is shown of levels of Th2-pattern cytokines postchallenge. Each of the
four panels illustrates individual mouse serum levels in duplicate and group geometric mean levels at 95% conﬁdence intervals
of IL-4, IL-5, IL-10, and GM-CSF, respectively. A Mann-Whitney test was made for group-wise comparison, and a P value of
0.05 was considered signiﬁcant.
Vaccine against CCHFV Journal of Virology
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FIG 4 (Continued)
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DISCUSSION
The development of a vaccine for CCHFV has been severely hampered due to the
lack of a suitable animal model and the requirement of a high-containment laboratory
to handle the virus. We along with others recently developed adult small-animal
models (mice deﬁcient in the type I IFN signaling pathway), which replicate human
FIG 5 Comparison of cytokine patterns prior to and postchallenge in groups A and B. In panels A to D, the cytokine patterns of four Th1-type
biomarkers are compared pre- and postchallenge; data are geometric means (95% conﬁdence intervals). In panels E to H, the cytokine
patterns of four Th2-type biomarkers are compared pre- and postchallenge; data are geometric means (95% conﬁdence intervals).
Vaccine against CCHFV Journal of Virology
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disease via a variety of inoculation routes, as good models for development of vaccines
and antivirals (5, 6).
In the current study, we used DNA plasmids expressing a ubiquitin-linked version of
Gc, Gn, and N and/or tc-VLPs to immunize IFNAR/ mice. The immunized mice were
challenged with CCHFV, and the immune responses before and after infection were
studied. In this work, we demonstrated a clear and 100% efﬁcient protective
FIG 5 (Continued)
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immunity against lethal CCHFV challenge if DNA plasmids expressing CCHFV pro-
teins Gc, Gn, and N were given three times epidermally/intradermally to CCHFV-
susceptible A129 IFNAR/ mice. We also found that a combination of DNA and VLP
immunization can protect against the disease.
In contrast to most other CCHFV vaccine studies, the present study investigated the
systemic pattern of eight selected Th1 and Th2 cytokines prior to and after the
challenge. We have investigated the levels of Th1-type biomarkers IFN-, TNF-, IL-12
p70, and IL-2, which were shown to be signiﬁcantly elevated in the DNA-immunized
and in the DNA- and tc-VLP-immunized A129 IFNAR/ mice prior to challenge. This
TABLE 1 Reactive B-cell epitopes
Epitope (peptide) Protein
No. of mice positive for the epitope
Group A (n  5) Group B (n  5)
TINCINLRASVFKEHREIEI Mucin-like 1 4
KIGKASTGFRKLLSEEPGDD Mucin-like 1 4
RLTSDGLARHVTQCPKRKEK Gn 3 3
––––––––––VTQCPKRKEKVEETELYLNL 2 3
CSIGSVNGFEIESHKCYCSL Gn 3 2
––––––––––IESHKCYCSLFCCPYCRHCS 4 3
LKGDRVNGHLIHKIESHFNT Gc 3 3
FIG 6 Serum IgG subclass reactivity for each pooled A129 IFNAR/ serum sample to CCHFV antigen. In
the top panel, the subclass pattern of the serum pools (indicated on the x axis) is shown prior to CCHFV
challenge, and in the bottom panel the serum IgG subclass pattern is shown at 10 days post-CCHFV
challenge (at day of sacriﬁce).
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may explain why these vaccinated animals were better prepared to respond to virus
challenge before a systemic infection could occur, and thereby full protection was
obtained. In addition, we observed a signiﬁcantly higher IFN- response in group A
(three DNA immunizations) than in group B (two DNA immunizations plus one tc-VLP
immunization), as well as a tendency toward higher IL-2, IL-12p70, and TNF- levels
postchallenge. Perhaps these slight differences between the two protected groups,
together with the IgG subclass pattern (Fig. 6) prior to challenge, suggest the level and
breath of Th1 proinﬂammatory responses necessary to ﬁnd a correlate of protection to
the adaptive cell-mediated immune response pattern. Interestingly, the mice immu-
nized with Ub-DNA plasmids did not demonstrate a clear Th2 response prior to the
challenge. This result was not completely unexpected since Th1-type immune re-
sponses are often seen with DNA plasmid vaccines and especially with DNA constructs
promoting ubiquitin pathway antigen processing (17). A comparison between the
cytokine proﬁles before and after challenge demonstrated that there is a shift from a
Th1 to Th2 response in groups A and B (Fig. 5A to H). However, the data from IgG
subclass proﬁling demonstrate that only group A2 shifted to Th2. The difference
between the outcomes of both cytokine and IgG subclass proﬁling could arise because
cytokine detection is much more sensitive than IgG subclass detection and/or because
the shift in IgG subclasses occurs later than 9 days postchallenge. However, we were
able to test the serum IgG subclass patterns before and after challenge. These results
conﬁrm the data from the cytokine analyses. Thus, in this study the animals with the
most elevated cell-mediated Th1 response combined with a good humoral Th2 type
immune response resisted weight loss and lethal challenge. All CCHFV antigen-
immunized mice developed detectable levels of neutralizing serum antibodies. How-
ever, animals with high neutralizing antibody titers and a Th2-type immune proﬁle
(tc-VLPs; group C) were only poorly protected. Thus, one may suggest that the
protective immunity correlated strongly with a dominant Th1-type immune proﬁle with
a balanced Th2-type biomarker response, and, as determined by serum IgG subclass
analysis, a strong IgG2a response was detected in the best-protected animals. Further-
more, in the two challenged and surviving groups (groups A and B), we could identify
linear IgG B-cell epitopes to the CCHFV envelope proteins. In 10 of 12 tested serum
samples (5 each in groups A and B) it was possible to identify responses to B-cell
epitopes. As far as we know, only one of these epitopes has been described in
CCHFV-immunized animals previously (18, 19). In two of the protected animals, serum
IgG reactivity against linear CCHFV peptide B-cell epitopes could not be shown.
Monoclonal antibodies against the Gn envelope protein have been described as
being more efﬁcient in protecting mice against lethal CCHFV challenge than monoclo-
nal antibodies to the Gc envelope protein (20). However, the Gc protein is considered
more immunogenic (21). The majority of B-cell epitopes are in general directed to
discontinuous epitopes that may be difﬁcult to identify with short linear peptides (22).
Therefore, it was interesting to see that this study could identify up to ﬁve different
B-cell epitope regions (Table 1), representing both the envelope proteins Gn and Gc.
Whether any of these epitopes are targets for virus-neutralizing antibodies remains
unclear and requires further exploration.
Recently, Buttigieg and colleagues (3) demonstrated that vaccination with the
attenuated poxvirus vector modiﬁed vaccinia virus Ankara expressing CCHFV glycopro-
teins (MVA-GP) can protect IFNAR/ mice against CCHFV challenge. The MVA-GP
vaccine induced comprehensive cellular and humoral immunity to CCHFV. The protec-
tion was suggested to be correlated with T-cell responses but not with neutralizing
antibody induction. Moreover, Canagloku and colleagues demonstrated that immuni-
zation with the cell culture-based inactivated vaccine elicited 80% protection against
challenge with CCHFV in IFNAR/ mice (23). These authors suggested that a strong
neutralizing antibody response is essential for the increased protection of IFNAR/
mice; however, the level of the T-cell-mediated immune response in mice was not
measured. Also in another study using Gn and Gc subunit recombinant proteins with
adjuvant, high titers of in vitro neutralizing antibodies were obtained in STAT1 knock-
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out A129 mice (21). However, no protection was seen in the vaccinated animals,
conﬁrming that serum neutralizing antibodies alone are not protective in mice
innately deﬁcient in IFN type I/II. Thus, it seems likely that a broader immunity is
required, including a cell-mediated immunity capable of clearing infected cells and
suppressing virus replication, as well as antibodies capable of virus neutralization,
antibody-dependent cellular cytotoxicity (ADCC), and complement-mediated viral
lysis (24). These protective correlates are totally different from what has been
described from Rift Valley fever (RVF) vaccine responses and passive immunother-
apy with neutralizing antibodies followed by challenge in mice. In RVF virus
infection, neutralizing antibodies correlate well with protection from infection and
pathogenesis in mice (10). One possible explanation for these differences may be
similar to what has been described in repeated dengue fever virus infections,
namely, that the developed antibodies may contain both virus-neutralizing and in
vivo infection-enhancing antibody populations and that the balance between these
types of serum antibodies may inﬂuence the outcome of the infection.
The viral glycoproteins are often a ﬁrst choice as antigens because they are
expressed on the particle surface and can elicit neutralizing antibodies. However, there
is strong sequence variation in the glycoprotein amino acids between CCHFV strains
(25). It has been reported that the nucleoproteins of bunyaviruses, more conserved at
the amino acid level, are also immunogenic and can confer partial protection after
challenge, as shown for Rift Valley fever virus (14, 16, 26). In our study, we included the
nucleoprotein N in the DNA immunization. Moreover, the nucleoprotein is also present
in a more natural structure in the tc-VLPs. While we did not ﬁnd any B-cell epitope
within this protein, the nucleoprotein could be internalized and processed into antigen-
presenting cells and contribute to T cell activation.
Interestingly, while the tc-VLPs for RVFV have been described to induce high
neutralizing antibody titers and protection of mice upon challenge (5, 14), we did not
observe such a correlation in the CCHFV system. The immunization with CCHFV tc-VLPs
conferred a high neutralizing antibody titer, but only 40% of the mice survived the
CCHFV infection. However, it is important to notice that the mice used in the RVFV
study were wild-type and IFN-competent mice, while the ones used in our study are IFN
incompetent. Indeed, wild-type mice do not show clinical signs of CCHFV infection, and
so far only the IFNAR/ and STAT1/ mice have been described to develop disease
(4, 5).
The tc-VLPs contain a ribonucleoprotein (RNP) complex consisting of a reporter
gene encapsidated by the nucleoprotein and bound by the viral RNA polymerase (13).
It has been demonstrated that incoming RNP complexes from several viral families,
including RNPs from RVFV tc-VLPs, are sufﬁcient to activate RIG-I and lead to IFN
production (15). Moreover, IFN production is a good predictor of vaccine efﬁciency.
tc-VLPs could induce better protection in an IFN-competent system, but, unfortunately,
the IFN response and its implication in immunization by tc-VLPs cannot be assessed in
our IFNAR/ mouse system.
In humans, CCHFV infection has been described to be divided into four phases, the
incubation of 1 to 13 days, the prehemorrhagic phase of 3 days up to 1 week, the
hemorrhagic phase of 2 or 3 days, and the ﬁnal convalescence period approximately 2
weeks postsymptoms (27, 28). In the mouse IFNAR/ model, the process is consider-
ably faster and more dramatic. This could explain why much of the speciﬁc immune
response needs to be rapid, alert, and active to provide protection.
In a human clinical trial where the inactivated Bulgarian CCHFV vaccine was tested,
mainly a cell-mediated immune response was shown (7). Up to four immunizations
were needed to obtain detectable neutralizing serum antibody titers.
In conclusion, it seems that a predominantly Th1-type immune response, combined
with mainly neutralizing antibodies, provides the most efﬁcient protective immunity
against CCHFV challenge given intraperitoneally (i.p.) in IFNAR/ mice.
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MATERIALS AND METHODS
Animals. Female, 6- to 8-week-old A129 IFNAR/ mice (The Jackson Laboratory, Sulzfeld, Germany)
were used. Mice were housed according to the Karolinska Institute ethical rules, and all experimental
protocols were approved by the regional Ethical Committee for animal research.
Virus. The CCHFV strain (Nigerian IbAr10200; the number of passages of this virus is not known) (5,
29) was serially diluted 10-fold and then titrated on Vero-E6 cells in 96-well plates. At 24 h postinfection,
cells were ﬁxed with 80% acetone and stained by immunoﬂuorescence. The number of ﬂuorescent foci
in each well was counted, and the titer was determined using a rabbit polyclonal anti-CCHFV nucleo-
capsid antibody, diluted in phosphate-buffered saline (PBS) containing 0.2% bovine serum albumin (BSA)
and 0.1% Triton X-100, followed by ﬂuorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody, as
described previously (30).
Plasmids. The plasmids for production of tc-VLPs, pCAGGS_V5_L_wt (encoding the polymerase),
pCAGGS_N (encoding the nucleoprotein), pT7riboSM2_vL_Ren (encoding the CCHFV-speciﬁc Renilla
[REN] minigenome), pCAGGS_GP (encoding the full open reading frame [ORF] of the M segment),
pCAGGS_T7 (encoding the T7 polymerase), and pGL3-Luc (encoding the ﬁreﬂy [FF] luciferase) were
described previously (13, 31).
The DNA vaccine plasmids pCMV-Ub-N, pCMV-Ub-Gc, and pCMV-Ub-Gn (termed pN, pGc and pGn,
respectively; CMV is cytomegalovirus) were generated using standard molecular cloning techniques.
They contain the coding sequence of solely the nucleoprotein N (in pN), the glycoprotein Gc (in pGc), or
the glycoprotein Gn (in pGn), each tethered to an N-terminal ubiquitin coding sequence. PCR was carried
out with Phusion HotStartII enzyme (FinnZymes), and PCR products were cloned into the pCMV-Ub
vector (16) using a BglII restriction site.
All ORFs derive from the CCHFV strain IbAr10200. The ORF of CCHFV nucleoprotein N was ampliﬁed
from the pCAGGS_N plasmid (31) using the following primers: CCHF_N_BglII_F (AGCCAGGAGATCTGAA
ACAAGATCGAGGTG) and CCHF_N_BglII_R (ATGCGCTGAGATCTAATGATGTTAGCACTGGTGG). The ORFs of
CCHFV glycoproteins Gn and Gc were ampliﬁed from the pCAGGS_GP plasmid (13) using the following
primers: the pair CCHFV_Gn_Esp_F (GCGTACCGTCTCAGATCTTCAGAAGAACCCAGTGATGAC) and CCHFV_
Gn_Esp_R (GGTCTCCGTCTCAGATCTTACAACCCAAGGAATTCTTTC) and the pair CCHFV_Gc_Esp_F (GCCAACCG
TCTCAGATCTTTCCTAGATAGTACAGCTAAAGG) and CCHFV_Gc_Esp_R (GGTCTCCGTCTCAGATCTGCCAATGTG
TGTTTTTGTAGAG), respectively. Roman letters are the sequences for CCHFV, and italicized letters are
extra bases added for the cloning (containing restriction site and extra). Correct insertion was conﬁrmed
by DNA sequencing. Maxipreps of all DNA vaccine plasmids were prepared using an EZNA Endo-Free
Plasmid DNA Maxi kit (Omega).
Production, ampliﬁcation, and puriﬁcation of tc-VLPs expressing Renilla luciferase. For produc-
tion of tc-VLPs, we employed a slightly modiﬁed version of a previously described protocol (13). Brieﬂy,
HuH-7 cells grown in T 175-cm2 ﬂasks in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 50 U/ml penicillin–50 g/ml streptomycin were
transfected with 11 g of pCAGGS_V5_L_wt, 3.6 g of pCAGGS_N, 3.6 g of pT7riboSM2_vL_Ren, 9.1 g
of pCAGGS_GP, 9.1 g of pCAGGS_T7, and 500 ng of a pGL3-Luc (ﬁreﬂy [FF] luciferase) control, using
GeneJammer transfection reagent (Agilent Technologies). Four hours after transfection, the medium was
replaced with fresh medium. Cell supernatants, designated passage 0, were collected at 72 h posttrans-
fection and centrifuged at 12,000  g for 5 min to remove cellular debris.
Ampliﬁcation of tc-VLPs was conducted by transfer of the cell supernatants onto new HuH-7 cells that
were pretransfected 20 h earlier with 11 g of pCAGGS_V5_L_wt, 3.6 g of pCAGGS_N, and 9.1 g of
pCAGGS_GP. Supernatants (passage 1) were collected 72 h later and ampliﬁed again to obtain tc-VLPs
(passage 2). Brieﬂy, HuH-7 cells pretransfected with plasmids encoding CCHFV L and N were infected with
10-fold dilutions of tc-VLP-containing supernatants and stained by immunoﬂuorescence against the
Renilla luciferase that is expressed by the VLPs. The titers were calculated on the basis of the dilution
factors and the ratio between the numbers of cell nuclei and Renilla-positive cells. To assess tc-VLP
ampliﬁcation, REN-Luc and FF-Luc activities were measured in cell lysates at each passage and after
polyethylene glycol (PEG) precipitation, using a Dual-Luciferase Reporter Assay System (Promega) and a
Centro LB 960 microplate luminometer (Berthold Technologies).
Immunization schedule. Three immunizations were performed with a 4-week interval between the
ﬁrst and the second immunizations and then with a 3-week interval between the second and the third
inoculations. Fifty micrograms of DNA plasmid/immunization/mouse (7 mice/group) was given via the
intradermal route by Biojector immunization, followed by electroporation immediately after injection of
DNA plasmids. VLPs were always injected intraperitoneally in 200 l of saline at 106 VLPs/mouse. The
immunization schedule is presented in Fig. 1A. All mice were bled 2 days prior to the ﬁrst immunization
and 3 weeks after each immunization. All mice were bled after CCHFV challenge (at day of sacriﬁce).
Serum was collected and kept frozen until analyzed.
IFNAR/ mice were divided into four groups (Fig. 1A). Two groups (named A and B, with 7 mice per
group) received a combination of the CCHFV DNA plasmids pGc, pGn, and pN during primary and
secondary immunizations. While group A received a further third dose of pGc, pGn, and pN, mice in
group B were given CCHFV tc-VLPs i.p. as a third dose. Further, group C (6 mice) was given three
immunizations with CCHFV VLPs, and group D (6 mice) received three immunizations with control
plasmid DNA (pCMV-Ub).
Detection of cytokines in serum. Cytokine responses were analyzed using a Pro Mouse cytokine
assay Th1/Th2 panel, according to the manufacturer’s protocol (Bio-Rad, Richmond, CA). In brief, 50 l
of serum in assay diluent was added to cytokine beads labeled with anti-Th1 (IFN-, interleukin-2 [IL-2],
and IL-12 p70) and Th2 (tumor necrosis factor- [TNF-], IL-4, IL-10, and granulocyte-macrophage
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colony-stimulating factor [GM-CSF]) cytokine antibodies. Standard curves for each cytokine were used to
determine cytokine concentration/milliliter of serum.
Challenge. CCHFV strain IbAr10200 was propagated in SW13 cells. Viral titers were determined using
standard methods (see above). At 6 weeks post-ﬁnal immunization, all mice were challenged with 400
focus-forming units (FFU) of CCHFV i.p. (40 times higher than lowest lethal dose) and then monitored for
up to 10 days with respect to clinical signs of disease, body weight, and survival. Due to the procedure
protocol for animal experiments at our biosafety level 4 (BSL-4) facility, we could not follow the surviving
mice longer that 10 days postchallenge.
Viral RNA detection. To inactivate virus, samples were treated with TRIzol LS reagent (Invitrogen,
Carlsbad, CA, USA) and subsequently phase separated by chloroform (Merck, Billerica, MA, USA) treat-
ment and centrifugation. Viral RNA was puriﬁed from the aqueous phase using a QIAamp Viral RNA
minikit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The extracted RNA was
analyzed by an S-segment-targeting real-time RT-PCR, as previously described (32). The same primers
were included in an in-house version of a SYBR green-based assay using a SuperScript III Platinum SYBR
green One-Step qRT-PCR kit (Invitrogen, Carlsbad, CA, USA). The cycling parameters were 20 min at 50°C,
5 min at 95°C, and 45 cycles of 10 s at 95°C, 10 s at 55°C, and 30 s at 68°C, followed by melting curve
analysis with wavelength ﬁlter F1/F2 performed at the end of the assays. The cycling reactions were
performed using a capillary Roche LightCycler 2.0 system. In addition, the primers were included in an
endpoint RT-PCR using the SuperScript III One-Step RT-PCR System with a Platinum Taq DNA polymerase
kit (Invitrogen, Carlsbad, CA, USA). The cycling conditions were 15 min at 50°C, 2 min at 94°C, 45 cycles
of 15 s at 94°C, 15 s at 50°C, and 30 s at 63°C, followed by 5 min at 68°C, using a GeneAmp PCR System
2700 (Applied Biosystems, Foster City, CA, USA).
Serology. An inactivated CCHFV antigen was used for coating at a 1:300 dilution in 0.05 M
Na2CO3-NaHCO3 buffer, pH 9.6, in ﬂat-bottomed 96-well plates (PolySorp, Nunc, Thermo Scientiﬁc). The
CCHFV antigen had been prepared by standard sucrose-acetone extraction from infected suckling mouse
brain. CCHFV antigen was inactivated by gamma irradiation (dose, 30 kGy). Phosphate-buffered saline
(PBS; pH 7.2) with 0.05% Tween 20 (Sigma-Aldrich) was used for blocking, as diluent, and as wash buffer.
Mouse serum was titrated in 2-fold steps from a starting dilution of 1:50 in duplicate wells. A pool of
known negative serum samples and a murine monoclonal antibody to CCHFV as a positive control were
included on every plate. Horseradish peroxidase-conjugated polyclonal rabbit anti-mouse immunoglob-
ulins (P0260; Dako) were used as tracers for the total Ig ELISA, and for the IgG subclass ELISAs
peroxidase-conjugated goat anti-murine Fc 1 (catalog number 115-035-205), Fc 2a (115-035-206), Fc
2b (115-035-207), Fc 2c (115-035-208), and Fc 3 (115-035-209), all from Jackson ImmunoResearch, were
used. An in-house substrate buffer (1 mM 3,5,3=,5=-tetramethylbenzidine in 0.1 M potassium citrate, pH
4.2, with 0.007% H2O2) was used for visualization of antibody binding. This reaction was stopped at a
standardized time point with 2 M H2SO4, and the A450 was measured in an ELISA reader. For every titrated
sample, A450 values were plotted against the sample dilution, and the equation for the linear part of the
curve was determined by regression analysis. Antibody titers were then calculated as the dilution that
would achieve an A450 value of 1. For total CCHFV Ig, a titer was determined for each individual mouse.
In each subclass ELISA, two serum pools from two to four individuals having the highest and lowest total
CCHFV Ig titers were titrated for each treatment group.
B-cell epitope mapping. A library of 288 CCHFV scan peptides (20-mers with an overlap of 10 amino
acids) was printed on microarray slides for B-cell epitope mapping (33, 34), covering the sequence of the
envelope glycoproteins of the Turkey strain (UniProt accession number C7F6X8) (peptides 1 to 168) and
the N-capsid of the Turkey strain (UniProt accession number C7F6X7) (peptides 242 to 288). This library
has been used and evaluated in a previous serology study with human CCHFV-positive sera (A. Fritzen,
C. Risinger, A. C. Hitzeroth, N. Viljoen, F. Burt, N. Kjeldmand, G. Korukluog˘lu, I. Christova, A. Mirazimi, and
O. Blixt, unpublished data). Due to the fact that the Gc and Gn regions are known to be highly conserved
(alignment between lbAr10200 [GenBank accession number Q8JSZ3, amino acids 516 to 1688] and the
Turkey strain [UniProt accession number C7F6X8, amino acids 516 to 1688] shows an identity of 92% and
a similarity of 96%), it was decided to perform the serology with the library at hand. Further epitopes
might be identiﬁed in a future study with a library that is optimized for the lbAr10200 strain. In brief,
serum was diluted 1:100 in PLI-P buffer (0.5 M NaCl, 3 mM KCl, 1.5 mM KH2PO4, 6.5 mM Na2HPO4, 3% BSA,
pH 7.4). The subarray wells were ﬁlled with 300 l of serum sample solution and incubated overnight (18
h) at room temperature on an orbital shaker. For the secondary staining, goat anti-mouse IgG-Cy5 (10
g/ml; Sigma-Aldrich) was diluted 1:500 in PLI-P buffer, and 300 l of this solution was used for
incubation at room temperature (RT) for 1 h on an orbital shaker. All incubation steps were performed
in a humidiﬁcation chamber and were separated by three wash steps in PBS. After a ﬁnal wash in PBS,
slides were rinsed in water and dried by centrifugation. The slides were scanned with a ProScanArray
microarray scanner. Spots were identiﬁed using automated spot ﬁnding with manual adjustments for
occasional irregularities. The mean value of relative ﬂuorescence intensity was used, and the spot
intensities were determined by subtracting the median pixel intensity of the local background from the
average pixel intensity within the spots. The results for ﬁve spots per peptide were averaged. To elucidate
serum IgG responses against linear B-cell epitopes in surviving CCHFV-challenged mice, we selected the
sera from group A and B mice at 10 days postchallenge for this study.
Neutralization assay. The titer of anti-CCHFV neutralizing activity in the serum was determined by
microneutralization assay. Serum samples were heat inactivated for 30 min at 56°C. Serial 2-fold dilutions
of serum were mixed with virus at a multiplicity of infection (MOI) of 0.05 (approximately 200 virus
particles) and incubated at 37°C for 1 h before being added to Vero cells on a 96-well plate in triplicate.
One hour later, medium was replaced with fresh DMEM supplemented with 2% FBS, 2 mM L-glutamine,
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and antibiotics (10 U/ml penicillin and 10 g/ml streptomycin), and cell culture was continued for a
further 24 h at 37°C. Cells were ﬁxed with ice-cold acetone-methanol (1:1) for 30 min and stained for viral
N for enumeration of ﬂuorescent foci, as described previously (35). The total numbers of infected cells
in positive controls and samples were counted, and the results were expressed as percent neutralization.
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